Aurinia Pharmaceuticals

89 articles with Aurinia Pharmaceuticals

• Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences

  1/8/2021

  Aurinia Pharmaceuticals Inc. announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner

• Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

  12/17/2020

  Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments

• Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

  12/15/2020

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship.

• Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  12/2/2020

  Aurinia Pharmaceuticals Inc. announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

• Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  11/20/2020

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted the newly appointed Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer, Stephen Robertson,

• Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference

  11/12/2020

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET. In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events” through the “I

• Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

  11/10/2020

  - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and investments totaled approximately $421 million at September 30, 2020 - - Conference call and webcast to be hosted today at 4:30pm EDT -

• Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020

  11/9/2020

  - Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differentiation as a potential best-in-class CNI -

• 

  Clinical Catch-Up: November 2-6

  11/9/2020

  It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
• 

  Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials

  11/3/2020

  Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.

• Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19

  10/27/2020

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation of an open-label exploratory trial evaluating the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with COVID-19 (SARS-CoV-2) – the VOCOVID study.

• Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020

  10/22/2020

  - Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic drug monitoring –

• Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com

  10/14/2020

  Aurinia Pharmaceuticals Inc. announced Time Is Nephrons, the first-ever lupus nephritis disease-state awareness campaign for healthcare professionals.

• Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 9 new employees non-qualified stock options to purchase an aggregate of 96,000 common shares, at a per share exercise price of $14.73 USD, the closing trading price on September 30, 2020.

• Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome

  9/28/2020

  Aurinia Pharmaceuticals Inc. announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.

• Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences - Sep 10, 2020

  9/10/2020

  Aurinia Pharmaceuticals Inc. announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences

• Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  9/4/2020

  Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83

• Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

  8/11/2020

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent operational highlights.

• Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

  8/4/2020

  Aurinia Pharmaceuticals Inc. announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT.

• Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

  7/30/2020

  Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close.